Ophthalmic neuromyelitis spectrum disease biomarker group, application thereof, protein chip and kit

A technology of neuromyelitis optica and biomarkers, applied in the field of biomedicine, to overcome cumbersome operations and less specimen consumption

Active Publication Date: 2020-08-11
RAYBIOTECH INC GUANGZHOU
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005]Currently, there are no reliable biomarkers, protein chips and kits that can accurately diagnose and differentiate neuromyelitis optica spectrum disorders (NMOSD) in healthy people

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmic neuromyelitis spectrum disease biomarker group, application thereof, protein chip and kit
  • Ophthalmic neuromyelitis spectrum disease biomarker group, application thereof, protein chip and kit
  • Ophthalmic neuromyelitis spectrum disease biomarker group, application thereof, protein chip and kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] The diagnostic criteria for patients with neuromyelitis optica spectrum disease (NMOSD) in Example 1 are as follows:

[0063] AQP4-IgG positive diagnostic criteria:

[0064] 1. Meet at least 1 core clinical symptom;

[0065] 2. AQP4-IgG positive (cell-based detection method);

[0066] 3. Exclude other possible diagnoses;

[0067] AQP4-IgG negative or no diagnostic criteria:

[0068] 1. In one or more clinical episodes, at least 2 core clinical features must be met, and all the following requirements must be met:

[0069] a. At least one core clinical feature must be optic neuritis, acute myelitis (LETM on MRI), or extreme posterior zone syndrome;

[0070] b. Spatial multiple (2 or more core clinical features appear);

[0071] c. Meet additional MRI requirements (depending on the actual situation);

[0072] 2. Use the most sensitive detection method available for negative or undetected AQP4-IgG;

[0073] 3. Exclude other possible diagnoses;

[0074] Core clinical features:

[0075] 1. Opt...

Embodiment 2

[0096] The example of the present invention is to detect the protein expression level of the serum of Example 1. The specific steps are as follows:

[0097] 1. Use sandwich-based antibody microarray to measure protein levels in serum. RayBiotech HumanCytokine Antibody Array Q4000 (QAH-CAA-4000, RayBiotech, Inc., Norcross, GA) was used for protein screening, which included a combination of 5 non-overlapping arrays to quantitatively measure 200 human cytokines.

[0098] Protein chip technology was used to determine the expression levels of 200 proteins in the 34 healthy control serum samples of Example 1, 41 NMOSD patient serum samples, and 12 MS patient serum samples: using a sandwich-based antibody microarray to measure serum levels Protein level. RayBiotech Human Cytokine Antibody Array Q4000 (QAH-CAA-4000, RayBiotech, Inc., Norcross, GA) was used for protein screening, which contains a combination of 5 non-overlapping arrays to quantitatively measure 200 human cytokines.

[0099]...

Embodiment 3

[0125] The examples of this application provide protein data conversion and graph generation, and the specific steps are as follows:

[0126] After calculating the concentration of the seven biomarkers in this application according to the specific software of the protein chip, perform data conversion before data analysis. The conversion formula is: log 2 (X+1). X is the concentration of different proteins corresponding to each sample. The transformed data is used for subsequent data analysis, including "principal component analysis, principal component analysis" (PCA), correlation heat map, model construction and weighted gene co-expression network analysis (WGCNA). All data processing and statistical tests are performed in the R language package (R Foundation for Statistical Computing, Vienna, Austria. URL https: / / www.R-project.org / ) and RStudio (RStudio, Inc., Boston, MAURL http) . All data is directly generated in RStudio, and then the pictures are integrated using Illustrat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of biological medicines and particularly relates to a biological marker group for optic neuromyelitis spectrum diseases, application of the biological marker group, a protein chip and a kit. The invention provides an optic neuromyelitis spectrum disease biomarker group which is characterized by comprising monocyte chemotactic protein-3, LIGHT, macrophage inflammatory protein-1 delta, insulin-like growth factor-2, a glucocorticoid induced tumor necrosis factor receptor, thrombopoietin and a herpes virus entry medium, wherein the LIGHT is a lymphotoxin analogue which can be induced and expressed on a T cell and competes with glycoprotein D of HSV to be combined with HVEM. The application fills the blank that no reliable and accurate product and method for diagnosing and identifying optic neuromyelitis lineage diseases exist clinically at present.

Description

Technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a set of biomarkers for neuromyelitis optica spectrum diseases and their applications, protein chips, and kits. Background technique [0002] Central nervous system demyelinating disease is an autoimmune system disease mainly characterized by multifocal and inflammatory demyelination of the central nervous system. Its clinical features mainly include repeated attacks, multiple remissions and relapses. At present, there is no effective treatment for demyelinating diseases of the central nervous system, mainly because the mechanism of demyelination and remyelination is not clear. In China, the incidence of neuromyelitis optica spectrum diseases ranks first in demyelinating diseases of the central nervous system. Neuromyelitis optica spectrum diseases include classic neuromyelitis optica (NMO) and neuromyelitis optica spectrum diseases (NMOSD). A rare and severe immune-r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2800/24G01N2800/285G01N2333/521G01N2333/47G01N2333/4745G01N2333/7151G01N2333/524G01N2333/70578
Inventor 黄若磐符聪聪张惠华
Owner RAYBIOTECH INC GUANGZHOU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap